Lili Zhang

Lili Zhang

Auto-generated profile, based on publicly available information

Lili Zhang

Department of Cardiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
DWDi Wang
Di Wang
ZWZhiyan Wang
Zhiyan Wang
LZLili Zhang
Lili Zhang
YWYi Wang
Yi Wang
Atherosclerosis has been identified as a chronic inflammatory disease of the arterial vessel wall. Accumulating evidence indicates that different cells from the tunica intima, media, adventitia, and perivascular adipose tissue not only comprise the intact and normal arterial vessel wall but also participate all in the inflammatory response of atherosclerosis via multiple intricate pathways. For instance, endothelial dysfunction has historically been considered to be the initiator of the development of atherosclerosis. The migration and proliferation of smooth muscle cells also play a pivotal role in the progression of atherosclerosis. Additionally, the fibroblasts from the adventitia and adipocytes from perivascular adipose tissue have received considerable attention given their special functions that contribute to atherosclerosis. In addition, numerous types of cytokines produced by different cells from the arterial vessel wall, including endothelium-derived relaxing factors, endothelium-derived contracting factors, tumor necrosis factors, interleukin, adhesion molecules, interferon, and adventitium-derived relaxing factors, have been implicated in atherosclerosis. Herein, we summarize the possible roles of different cells from the entire arterial vessel wall in the pathogenesis of atherosclerosis.

1 November 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Open access
LZLili Zhang
Lili Zhang
YZYifan Zhang
Yifan Zhang
ZMZhihui Ma
Zhihui Ma
YZYanrong Zhu
Yanrong Zhu
ZCZhong Chen
Zhong Chen
Coronary heart disease (CHD) is a multifactorial disease associated with complicated altered metabolic pathways, especially when it occurs with type 2 diabetes (T2D). Identification of metabolic changes could provide further understanding of the underlying pathological link between with CHD and T2D. In this study, 61 controls, 30 consecutive patients with only T2D, 188 with confirmed CHD among which 50 also having T2D were enrolled. Quantitative 1H nuclear magnetic resonance (1H NMR) based metabonomic approach was used to obtain the plasma metabolic profiles of the study samples. Multivariate principal component analysis and orthogonal partial least-squares discriminant analysis (OPLS-DA) were used to evaluate the differences of metabolites. Compared with controls, there were significant differences in CHD patient with T2D groups including BCAAs (isoleucine, leucine, and valine) and phenylalanine by using quantitative metabolomic profiling (all p < 0.05). With OPLS-DA, the results showed that, compared to CHD patients without T2D, there had higher levels of metabolites for leucine, valine, fumarate, tyrosine, and phenylalanine in the plasma of CHD patients with T2D. Moreover, the CHD patients with T2D showed modified phenylalanine, tyrosine and tryptophan biosynthesis, valine, leucine and isoleucine biosynthesis and degradation compared with CHD patients without T2D. By 1H NMR based quantitative metabolomic method, our findings suggest that T2D has important effects on BCAAs and AAAs metabolism in CHD patients indicating altered cardiac energy metabolism and activated signaling pathway could be potential targets for therapy in CHD disease combined with T2D.

1 September 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YLYingyu Liu
Yingyu Liu
CKChanggui Kou
Changgui Kou
WBWei Bai
Wei Bai
XLXinyu Liu
Xinyu Liu
YSYan Song
Yan Song
YXYing Xin
Ying Xin
Objectives: A Bayesian network meta-analysis (NMA) was conducted in patients with head and neck cancers (HNCs) to estimate the efficacy and safety of treatment with conventional fractionation radiotherapy (CF), conventional fractionation chemoradiotherapy (CF_CRT), hyperfractionated radiotherapy (HF), hyperfractionated chemoradiotherapy (HF_CRT), accelerated fractionation radiotherapy, accelerated fractionation chemoradiotherapy, accelerated hyperfractionated radiotherapy (HART) or accelerated hyperfractionated chemoradiotherapy (HACRT) to identify superior treatments to aid in clinical decisions. Methods: PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for potentially eligible randomized controlled trials up to December 2016. Overall survival (OS), disease-free survival (DFS) and locoregional control (LRC) were considered efficacy outcomes, whereas acute toxicity and late toxicity on skin and mucosa were considered safety outcomes. The surface under the cumulative ranking curve (SUCRA) was calculated to rank each treatment in each index. Results: Data from 72 trials with 21,868 participants were included in the analysis. Concerning OS, all treatments were associated with a significant advantage compared to CF alone, with HR effect sizes ranging from 0.64 to 0.83, and HACRT was significantly more effective than all the other treatments. The network comparisons of both HACRT vs HART and HF_CRT vs HF demonstrated a higher OS benefit, with an HR of 0.78 (95% credible interval [CrI]: 0.64–0.95) and 0.78 (95% CrI: 0.61–0.99), respectively. The results of SUCRA indicated that HACRT had the best ranking for OS and LRC, HF_CRT for DFS, HART for acute and late skin toxicity, CF_CRT for acute mucosal toxicity and HF_CRT for late mucosal toxicity. Conclusion: The NMA results support the notion that HACRT is the preferable treatment modality for HNCs because it has better rankings in all three efficacy indexes, although it does present a high risk of acute mucosal toxicity.

18 March 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
JZJianqiu Zhao
Jianqiu Zhao
XZXinyu Zhang
Xinyu Zhang
LZLili Zhang
Lili Zhang
SWShouling Wu
Shouling Wu
SCShuohua Chen
Shuohua Chen
WLWen Li
Wen Li
Objectives To investigate the association between systolic blood pressure time in target range (SBP-TTR) and the risk of all-cause mortality in patients with atherosclerotic cardiovascular disease (ASCVD). Design Analysis of data from a prospective cohort. Setting This study used data from the Kailuan Study. Participants diagnosed with ASCVD from 11 hospitals affiliated with the Kailuan Group in Tangshan, China were included in the analysis. Participants We included 6732 participants who developed ASCVD between 1 July 2006 and 31 December 2013, and who had two or more blood pressure measurements recorded between the ASCVD diagnosis date and 31 December 2017. All participants were followed up until 31 December 2022. Outcome measures SBP-TTR was defined as the proportion of time during which SBP remained within the target range, calculated using the linear interpolation method. Participants were stratified into five SBP-TTR categories: 0%, >0% to <25%, 25% to <50%, 50% to <75% and ≥75%. Associations between SBP-TTR categories and all-cause mortality were evaluated. Results When the target SBP range was defined as 120–140 mm Hg, compared with the SBP-TTR=0% group, the multivariable-adjusted HRs (95% CIs) for all-cause mortality were 0.92 (0.78 to 1.07), 0.82 (0.72 to 0.94), 0.79 (0.68 to 0.92) and 0.76 (0.65 to 0.89) for the SBP-TTR groups of <25%, 25% to <50%, 50% to <75% and ≥75%, respectively. For each SD increase in SBP-TTR, the risk of all-cause mortality decreased, with a multivariable-adjusted HR of 0.90 (95% CI 0.85 to 0.95). The inverse association between SBP-TTR and all-cause mortality was more pronounced in younger participants (aged <67 years) (p for interaction=0.008). Conclusions This study demonstrated a significant inverse association between SBP-TTR and all-cause mortality among patients with ASCVD. The association between maintaining SBP within the 120–140 mm Hg target range and reduced mortality was more evident in younger individuals. These findings suggest that sustained and stable blood pressure control may improve long-term survival in patients with ASCVD. Trial registration number ChiCTR-TNC-11001489.

1 January 2026 in IEEE Transactions on Electromagnetic Compatibility
Verified
Journal Article
Closed access
TQTao Qin
Tao Qin
LZLili Zhang
Lili Zhang
XZXue Zhang
Xue Zhang
LWLei Wang
Lei Wang
DHDong Huang
Dong Huang
WZWenbin Zhao
Wenbin Zhao